ORTINLAB.NS

Ortin Laboratories Limited [ORTINLAB.NS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ORTINLAB.NS Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

ORTINLAB.NS

Top 10 Correlated Stocks

ORTINLAB.NS

In the News

ORTINLAB.NS Financial details

Company Rating

Market Cap

142.71M

Income

-3.43M

Revenue

68.58M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

14 Feb 2023

P/E

-41.6

Forward P/E

PEG

4.05

P/S

2.08

P/B

1.35

P/C

P/FCF

Quick Ratio

0.05

Current Ratio

0.8

Debt / Equity

LT Debt / Equity

0.23

EPS (TTM)

-0.03

EPS next Y

EPS next Q

EPS this Y

-142.24%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

-36.5%

Revenue Q/Q

47.08%

EPS Q/Q

5500%

SMA20

-14.84%

SMA50

-18.55%

SMA100

-20.23%

Inst Own

Inst Trans

ROA

-2%

ROE

-3%

ROC

Gross Margin

44%

Oper. Margin

Profit Margin

-5%

Payout

Shs Outstand

8.13M

Shs Float

4.85M

Target Price

52W Range

16.2-31.7

52W High

-44.52%

52W Low

+7.5%

RSI

24.03

Rel Volume

0.07

Avg Volume

71.5K

Volume

4.78K

Perf Week

-12.02%

Perf Month

-24.23%

Perf Quarter

-26.81%

Perf Half Y

-26.65%

Beta

1.15243

Volatility

1.49%, 1.66%

Prev Close

1.47%

Price

17.2

Change

-1.71%

ORTINLAB.NS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric	2018-03-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31
Revenue per share	98.02	200.79	241.24	10.02	10.12
Net income per share	0.84	1.57	-0.69	1.16	-0.49
Operating cash flow per share	1.92	4.07	7.66	22.13	2.65
Free cash flow per share	0.39	0.21	3.82	22.13	2.49
Cash per share	1.33	1.1	1.18	0.22	0.73
Book value per share	29.61	30.86	29.29	13.93	13.47
Tangible book value per share	29.61	30.86	29.29	13.93	13.47
Share holders equity per share	29.61	30.86	29.29	13.93	13.47
Interest debt per share	29.31	34.7	36.89	9.59	8.55
Market cap	313.39M	242.24M	118.58M	252.68M	183.89M
Enterprise value	516.06M	488.02M	384.28M	321.84M	240.42M
P/E ratio	46.14	18.93	-21.03	26.72	-46.12
Price to sales ratio	0.39	0.15	0.06	3.09	2.23
POCF ratio	20.11	7.32	1.9	1.4	8.54
PFCF ratio	98.95	140.19	3.82	1.4	9.07
P/B Ratio	1.3	0.97	0.5	2.23	1.68
PTB ratio	1.3	0.97	0.5	2.23	1.68
EV to sales	0.65	0.3	0.2	3.94	2.92
Enterprise value over EBITDA	10	8.6	7.48	24.85	41.85
EV to operating cash flow	33.12	14.74	6.17	1.78	11.17
EV to free cash flow	162.95	282.42	12.37	1.78	11.86
Earnings yield	0.02	0.05	-0.05	0.04	-0.02
Free cash flow yield	0.01	0.01	0.26	0.71	0.11
Debt to equity	2.06	3.19	3.89	0.87	0.89
Debt to assets	0.67	0.76	0.8	0.47	0.47
Net debt to EBITDA	3.93	4.33	5.17	5.34	9.84
Current ratio	1.26	1.14	1.1	0.78	0.76
Interest coverage	1.35	1.79	1.52	1.1	0.35
Income quality	2.29	2.59	-11.04	19.07	-5.4
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.01	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	-0.8	-0.95	-0.5	0	-0.06
Capex to revenue	-0.02	-0.02	-0.02	0	-0.02
Capex to depreciation	-0.74	-1.79	-1.6	0	-0.43
Stock based compensation to revenue	0	0	0	0	0
Graham number	23.59	33.06	21.38	19.07	12.18
ROIC	0.07	0.09	-0.05	0.33	0.01
Return on tangible assets	0.01	0.01	0	0.04	-0.02
Graham Net	-44.88	-74.56	-82.14	-10.82	-10.18
Working capital	107.33M	98.65M	85.85M	-17.61M	-18.61M
Tangible asset value	240.78M	250.94M	238.16M	113.56M	109.57M
Net current asset value	27.7M	20.48M	-2.9M	-37.85M	-39.98M
Invested capital	0.87	1.01	1.16	0.61	0.56
Average receivables	0	0	0	0	0
Average payables	99.49M	320.89M	537.99M	306.7M	10.63M
Average inventory	208.35M	304.88M	434.29M	258.66M	17.86M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	105.09	126.25	136.69	123.67	61.78
Days of inventory on hand	152.23	98.03	113.68	169.25	136.6
Receivables turnover	0	0	0	0	0
Payables turnover	3.47	2.89	2.67	2.95	5.91
Inventory turnover	2.4	3.72	3.21	2.16	2.67
ROE	0.03	0.05	-0.02	0.08	-0.04
Capex per share	-1.53	-3.86	-3.84	0	-0.15

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	2.02	2.79	3.22	0.97	1.42
Net income per share	-0.11	-0.55	-0.52	0.1	0.56
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0	0.72	0	0.39	0
Book value per share	0	13.35	0	13.05	0
Tangible book value per share	0	13.35	0	13.05	0
Share holders equity per share	0	13.35	0	13.05	0
Interest debt per share	0	7.78	0	8.62	0
Market cap	273.36M	185.53M	174.01M	190.27M	193.31M
Enterprise value	0	242.05M	0	257.41M	0
P/E ratio	-75.68	-10.23	-10.2	58.87	10.6
Price to sales ratio	16.48	8.09	6.64	24.19	16.71
POCF ratio	0	0	0	0	0
PFCF ratio	0	0	0	0	0
P/B Ratio	0	1.69	0	1.79	0
PTB ratio	0	1.69	0	1.79	0
EV to sales	0	10.55	0	32.73	0
Enterprise value over EBITDA	0	-182.54	0	-113.5	0
EV to operating cash flow	0	0	0	0	0
EV to free cash flow	0	0	0	0	0
Earnings yield	0	-0.02	-0.02	0	0.02
Free cash flow yield	0	0	0	0	0
Debt to equity	0	0.89	0	0.9	0
Debt to assets	0	0.47	0	0.47	0
Net debt to EBITDA	0	-42.63	0	-29.6	0
Current ratio	0	0.76	0	0.8	0
Interest coverage	0.43	-1.33	1.34	-3.51	5.42
Income quality	0	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	12.88	0	5.4	0
ROIC	0	-0.01	0	0	0
Return on tangible assets	0	-0.02	0	0	0
Graham Net	0	-10.09	0	-10.14	0
Working capital	0	-18.61M	0	-13.19M	0
Tangible asset value	0	109.57M	0	106.12M	0
Net current asset value	0	-39.98M	0	-41.73M	0
Invested capital	0	0.56	0	0.65	0
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	52.5	0	128.27	0
Days of inventory on hand	0	116.08	0	328.72	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	1.71	0	0.7	0
Inventory turnover	0	0.78	0	0.27	0
ROE	0	-0.04	0	0.01	0
Capex per share	0	0	0	0	0

ORTINLAB.NS Frequently Asked Questions

What is Ortin Laboratories Limited stock symbol ?

Ortin Laboratories Limited is a IN stock and trading under the symbol ORTINLAB.NS

What is Ortin Laboratories Limited stock quote today ?

Ortin Laboratories Limited stock price is $17.2 today.

Is Ortin Laboratories Limited stock public?

Yes, Ortin Laboratories Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 71.5K
Market Capitalization 142.71M
Employee 29
CEO Mr. Sanka Murali Krishna Murthy
Headquarters Hyderabad,IN
IPO Date 2015-08-21
Website https://www.ortinlabsindia.com

Ortin Laboratories Limited manufactures and trades in pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti biotics-quinolones, anti biotic-pencillins, antifungal, cephalosporins, and macrolides; and anti anginal and cardio vascular, and antifungal products. The company's formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodics, calcium preparations, iron preparations, anti arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti retroviral products. In addition, it provides active pharmaceutical ingredient (API) intermediates comprising anti retro viral, anti diabetics, analgesics and antipyretics, anti biotic, antifungal, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company offers services in the areas of process development, process characterization, analytical research and development, assay development, and product characterization; and diagnostic services, including development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; and operates as a merchant exporter of pharmaceutical finished formulations. Ortin Laboratories Limited was incorporated in 1986 and is headquartered in Hyderabad, India.